Jinming Cao

Dr. Jinming Cao

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 October 2025 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
MWMengyao Wu
Mengyao Wu
GLGe Li
Ge Li
YLYecheng Li
Yecheng Li
KCKai Chen
Kai Chen
MXMengdan Xu
Mengdan Xu
JCJinming Cao
Jinming Cao
Introduction: Pancreatic ductal adenocarcinoma (PDAC) continues to exhibit resistance to immunotherapy. In this study, we evaluated the efficacy of combining immunotherapy with chemotherapy for the treatment of advanced pancreatic cancer. Additionally, we employed a multimodal analytical approach to elucidate the immune landscape and conduct transcriptomic profiling in PDAC.Methods: A retrospective analysis was conducted on the clinical data of 52 patients diagnosed with advanced PDAC who underwent a combined treatment regimen of immunotherapy and chemotherapy. The study evaluated the objective response rate (ORR), disease control rate (DCR), and progression-free survival (PFS). To characterize the immune landscape in treatment-naive pancreatic ductal adenocarcinoma (PDAC) tumors and in the systemic circulation, flow cytometry, multiplex immunohistochemistry (mIHC), and whole transcriptome sequencing were employed.Results: The study reported an ORR of 32.7%, a DCR of 67.3%, and a 6-month PFS rate of 38.5%, with a median PFS of 5.5 months. Patients treated with a combination of immunotherapy and gemcitabine achieved the longest PFS. The first-line treatment cohort exhibited a significantly higher DCR (79.3% vs. 52.2%, P = 0.038) and a longer median PFS (6.6 vs. 3.5 months, P = 0.032) compared to the second-line treatment cohort. The efficacy of treatment varied depending on the drug combinations used. Flow cytometry analysis revealed a greater frequency of CD45- CD64+ cells in the peripheral blood of patients with progressive disease (PD) compared to those with a partial response (PR). Multiplex immunofluorescence (MIF) analysis indicated an increased intratumoral infiltration of CD8+ T cells and CD137+ CD8+ T cells in patients with PR. Whole transcriptome sequencing (WTSS) identified key genes involved in immune regulation, signal transduction, and digestive function. Hemopexin (HPX) and regulatory factor X-associated protein (RFXAP) were upregulated in PR patients and showed a positive correlation with survival, whereas Interleukin-6 (IL-6) expression was linked to poor prognosis.Conclusions: These findings indicate that immunochemotherapy shows potential for the treatment of advanced PDAC. Our study elucidates the immune landscape associated with PDAC and provides critical insights for the identification of prospective therapeutic targets, which could guide the development of innovative combination immunotherapy strategies.

1 January 2026 in Gland Surgery
Verified
Journal Article
Open access
MZMin Zhao
Min Zhao
XSXinyu Shi
Xinyu Shi
RSRunjie Shui
Runjie Shui
YJYuxuan Jin
Yuxuan Jin
JCJinming Cao
Jinming Cao
BZBin Zhang
Bin Zhang
Lateral lymph node metastasis (LLNM) and skip lymph node metastasis (SLNM) in papillary thyroid carcinoma (PTC) are generally unpredictable, especially in adolescents and young adults (AYAs). This study aims to investigate the risk factors associated with LLNM and skip SLNM in AYAs with PTC. This retrospective analysis was performed on the medical records of AYAs with PTC who underwent total or near-total thyroidectomy or lobectomy, along with central lymph node dissection (CLND) and lateral lymph node dissection (LLND) at The First Affiliated Hospital of Soochow University from January 2017 to December 2023. Variables identified as significant in the univariate analysis were further assessed using multivariate analysis. Continuous variables deemed significant were analyzed using receiver operating characteristic (ROC) curve analysis to establish optimal cut-off values. Logistic regression analysis was then employed to identify independent risk factors for LLNM and SLNM in AYAs with PTC. Among the 545 AYAs with PTC, 480 individuals (88.1%) exhibited LLNM, with 54 of these 480 patients (11.3%) demonstrating SLNM. Univariate and multivariate analyses identified the diameter of the largest tumor [P<0.001, odds ratio (OR) =2.768, 95% confidence interval (CI): 1.544–4.962] and the number of central lymph node metastasis (CLNM) (P=0.001, OR =3.888, 95% CI: 1.701–8.888) as independent predictors for LLNM. Furthermore, the number of LLNM (P=0.007, OR =0.295, 95% CI: 0.122–0.712) was identified as an independent factor for SLNM. ROC curve analysis determined that the optimal cut-off values for the diameter of the largest tumor, the number of CLNM, and the CLNM/ CLND ratio as risk factors for LLNM in AYAs with PTC were 1.1 cm, 3, and 0.3, respectively. Similarly, the optimal cut-off values for the diameter of the largest tumor, the number of LLNM, and the LLNM/LLND ratio for predicting SLNM were 1.2 cm, 5, and 0.2, respectively. This study demonstrated that the diameter of the largest tumor greater than 1.1 cm and a number of CLNM equal to or greater than 3 were independent risk factors for LLNM in AYAs with PTC. Additionally, a number of LLNM equal to or less than 5 was identified as a risk factor for SLNM.